Thank you to everyone who supported our work this year including donors, patients, and healthy controls in our trials.
#polybio2026countdown
No.11 on our 2026 countdown: PolyBio began a collaboration with 60 Degrees Pharma on a clinical trial of Tafenoquine for Chronic Babesiosis. The trial is a crucial step forward in finding effective therapies for the disease, which currently has no FDA-approved treatments.
#polybio2026countdown
Read the project summary here:
polybio.org/projects/dev...
#polybio2026countdown
2/ Read the full news story here: polybio.org/polybio-rese...
#polybio2026countdown
No.8 on our list of influential PolyBio moments in 2025: the expansion of LIINC to study pre-2019 ME/CFS. The study will investigate key biological drivers of ME/CFS, including persistent gut enterovirus infections and T-cell over-activation in the CNS.
#polybio2026countdown
2025 was the year that PolyBio began launching several clinical trials—importantly, the RCT of repurposed HIV antivirals Truvada & Maraviroc for Long Covid at the CoRE clinic.
#polybio2026countdown
One of our favourite highlights of the year at PolyBio: Dr. Amy Proal’s TedX talk on the pathogen drivers of human aging.
“As [chronic pathogens] live in us, they can create proteins & products that actively distort the signalling of our own human genes.”
#polybio2026countdown
A key contribution to the field this year by Dr. Amy Proal, PolyBio President & CEO, was her LA Times Op-Ed—a call-to-arms to both government agencies and private organizations to support Long Covid clinical trials.
www.latimes.com/opinion/stor...
#polybio #polybio2026countdown
Learn more about the study and its results here: polybio.org/polybio-and-...
#polybio2026countdown
Next up in PolyBio’s influential moments of 2025: we began supporting a clinical trial of low-dose Rapamycin for Long Covid at NYC’s Mount Sinai CoRE clinic. The ongoing study is assessing how patients’ immune markers (i.e. T-cell function) change over time. #polybio2026countdown
One of PolyBio’s most notable moments of 2025 was the publication of the ‘Long Covid Roadmaps paper,’ which brought together 30+ global experts. The paper was the first of its kind, discussing treatment strategies targeting the SARS-CoV-2 viral reservoir in Long Covid.
#polybio2026countdown
We’re counting down to the new year in the best way we know how: by looking back at 12 of PolyBio’s most influential moments of 2025. Follow along with us to recap key research in the complex chronic illness space this year. #polybio2026countdown